CASI Pharmaceuticals Inc - Asset Resilience Ratio
CASI Pharmaceuticals Inc (CASI) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how CASI Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check CASI Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CASI Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CASI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: CASI Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
CASI Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare CASI Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for CASI Pharmaceuticals Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for CASI Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.89% | $2.62 Million | $53.67 Million | -13.30pp |
| 2023-12-31 | 18.18% | $13.69 Million | $75.27 Million | +13.79pp |
| 2022-12-31 | 4.39% | $4.22 Million | $96.23 Million | -2.74pp |
| 2021-12-31 | 7.14% | $9.87 Million | $138.30 Million | -0.15pp |
| 2020-12-31 | 7.29% | $9.31 Million | $127.73 Million | +6.68pp |
| 2019-12-31 | 0.61% | $625.00K | $102.63 Million | -0.20pp |
| 2018-12-31 | 0.80% | $912.20K | $113.41 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $45.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $27.71 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.83 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.31 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $15.51 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $8.98 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $3.24 Million | -- |
| 2010-12-31 | 0.32% | $25.82K | $8.04 Million | -0.22pp |
| 2009-12-31 | 0.54% | $54.07K | $10.07 Million | -25.56pp |
| 2008-12-31 | 26.10% | $7.55 Million | $28.92 Million | -7.99pp |
| 2007-12-31 | 34.09% | $18.07 Million | $53.01 Million | -19.17pp |
| 2006-12-31 | 53.26% | $29.67 Million | $55.72 Million | +2.00pp |
| 2005-12-31 | 51.26% | $18.67 Million | $36.43 Million | +15.44pp |
| 2004-12-31 | 35.82% | $14.11 Million | $39.40 Million | +30.52pp |
| 2003-12-31 | 5.30% | $2.13 Million | $40.15 Million | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more